Stay updated with breaking news from Special Protocol Agreement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that...
NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.
RADNOR - NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar...
Biopharmaceutical company NRx Pharmaceuticals, Inc. (NRXP) announced Monday that it has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.
Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted...